search
Back to results

Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease. (ENDOCIR)

Primary Purpose

Crohn Disease

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Surgical resection
Sponsored by
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Crohn Disease focused on measuring crohn

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-80 years of age.
  • Crohn's disease with predominantly de novo fibrotic stenosis* confirmed by endoscopic and radiological tests, accessible by endoscopy (colonoscopy).
  • Patients with known stenosis previously treated with stenting and/or dilation performed over one year before the date of inclusion.
  • Symptomatology of intestinal occlusion-subocclusion.
  • Refractoriness to conventional medical treatment (non-response to the usual accelerated step-up therapeutic approach).
  • Stenosis length < 10 cm.
  • Maximum of 2 stenoses.
  • Informed consent from patient.

Exclusion Criteria:

  • No informed consent from the patient.
  • Complicated stenosis with abscess, fistula or significant activity associated with CD not limited to the area of the stenosis.
  • Patients with known stenosis previously treated with stenting and/or dilation performed < 1 year before the date of inclusion.
  • Pregnancy or lactation.
  • Any clinical situation that prevents the performance of endoscopy or surgery.
  • Stenosis not accessible by endoscopy.
  • Asymptomatic patient.
  • Stenosis length ≥ 10 cm.
  • Presents with > 2 stenoses.
  • Severe coagulation disorders (platelets < 70000; INR > 1.8).

Sites / Locations

  • Hospital Germans Trias i Pujol
  • Hospital Universitario de Bellvitge
  • Althaia, xarxa assistencial universitaria de Manresa
  • Consorci Corporació Sanitària Parc Taulí
  • Hospital Moisès Broggi
  • Hospital Mutua de TerrassaRecruiting
  • Hospital Universitario de Cáceres
  • Clínica Girona
  • Hospital Josep Trueta
  • Hospital de Inca
  • Hospital Universitari Arnau de Vilanova
  • Hospital Universitario La Paz
  • Hospital Universitario Ramon y Cajal
  • Hospital de Terrassa
  • Hospital Clínico de Valencia
  • Hospital Universitari La Fe

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

EBD group

SEMS group

Arm Description

Post-procedural admission in the Short Stay Unit (SSU). Superficial sedation by endoscopist or anesthesiologist depending on the center. Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion. A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation. Dilation failure will be considered if > 2 dilations are required.

Post-procedural admission in the Short Stay Unit (SSU). Superficial sedation by endoscopist or anesthesiologist depending on the center. Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion. Removal time of the prosthesis 4 weeks.

Outcomes

Primary Outcome Measures

Quality of life of patients
Percentage of patients with an increase of more than 30 points in the Inflammatory Bowel Disease Questionnaire (IBDQ-32) quality of life index. The higher the better.

Secondary Outcome Measures

Percentage of patients with clinical recurrence
Percentage of patients with clinical recurrence (scale of obstructive symptoms 0-6) and costs. The lower the better.
Percentage of complications
Percentage of complications and costs.

Full Information

First Posted
March 25, 2020
Last Updated
February 23, 2023
Sponsor
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
search

1. Study Identification

Unique Protocol Identification Number
NCT04330846
Brief Title
Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease.
Acronym
ENDOCIR
Official Title
Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Crohn's Disease. Endoscopic Treatment (Self-expanding Metal Prosthesis/Ballon Dilation) vc Surgical Resection (ENDOCIR STUDY)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 29, 2022 (Actual)
Primary Completion Date
April 1, 2024 (Anticipated)
Study Completion Date
April 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Stenosis is one of the most frequent complications in patients with Crohn's disease (CD), causing greater morbidity and increasing the probability of repeated surgery and short bowel syndrome (1-3). Endoscopic balloon dilation (EBD) is clearly the treatment of choice for short stenoses located at the anastomosis of previous surgeries (4-6). However, there is no scientific evidence for determining the most appropriate treatment for de novo stenosis less than 10 cm in length (surgical versus endoscopic treatment), both in terms of efficacy and complications. Neither has it been established which of these two approaches has a greater impact on the quality of life of patients and on costs.
Detailed Description
In many cases, a surgical approach allows for the removal of the entire inflamed intestine. However, the percentage of post-surgical recurrence per year after surgery is 80-85% (7), decreasing to 40% in patients who begin preventive immunosuppressive treatment in the immediate post-surgery period (8). This means that more than 40% of patients will require combined immunosuppression to keep CD under control one year after surgery. Endoscopic treatment does not remove the affected intestine. However, it has a long-term therapeutic efficacy of 50-60% with a very low percentage of complications (4-6%). A large number of studies have shown that patients' quality of life improves when CD is properly controlled, either through medical or surgical treatment (9). However, there are no studies evaluating the quality of life of patients after endoscopic treatment. Neither are there comparative studies of the costs of the two procedures. However, a recent study comparing the cost of 38 endoscopic procedures with their surgical equivalent suggested that, in most cases, the cost of endoscopic treatment is four times lower (10). The European Crohn's and Colitis Organization (ECCO) guidelines on the management of de novo stenosis in patients with CD recommend surgery as the first option, based on expert opinion (Level of Evidence 4), although there are no studies comparing the two treatment modalities (11,12). A Spanish multicenter study coordinated by researchers involved in the present project (Andujar X, et al)(13), which included the largest published series of endoscopic treatment with dilation in patients with CD to date, shows that therapeutic success with EBD in de novo stenoses is achieved in a large percentage of cases, with results similar to those obtained in post-surgical stenoses (73% vs 84%). In addition, CD stenoses can be treated effectively with self-expanding metal stents (SEMS), and it has been suggested that these may be particularly indicated in patients who are refractory to balloon dilation, including both de novo and anastomotic stenosis patients (14-17). Therefore, in order to compare the efficacy of these two endoscopic treatments, the PROTDILAT study (IP: C Loras. Project FIS nº Pl13/01226 and Clinical Trials. Gov nº NCT02395354) was designed, and is currently in the final manuscript writing phase (100 patients included). The final results (Andújar X, UEGW 2019)(18) confirm that both procedures are effective and safe in the treatment of both post-surgical and de novo stenosis, while showing the therapeutic superiority of EBD over SEMS when the results are evaluated globally (80.5 vs 51.3 %; primary end point). However, this difference is not observed in the subanalysis of patients with stenosis ≥4 cm (LBD: 66.7% vs PMA: 63.6%) but with a significantly lower cost in EDB treatment (EDB 1,212.41 euros vs PMA 3,615.07 euros). Therefore, SEMS may have a role to play in longer stenosis in which EBD has proven to be less efficacious. This work has been conceived as an exploratory proof of concept study, given that there are currently no studies comparing surgical and endoscopic approaches and it is therefore difficult to calculate the adequate sample size.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn Disease
Keywords
crohn

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A prospective multicenter randomized comparative study of the treatment of de novo stenosis due to CD, comparing endoscopic treatment (stent or EBD) vs. surgical resection (SR). The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
EBD group
Arm Type
Experimental
Arm Description
Post-procedural admission in the Short Stay Unit (SSU). Superficial sedation by endoscopist or anesthesiologist depending on the center. Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion. A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation. Dilation failure will be considered if > 2 dilations are required.
Arm Title
SEMS group
Arm Type
Experimental
Arm Description
Post-procedural admission in the Short Stay Unit (SSU). Superficial sedation by endoscopist or anesthesiologist depending on the center. Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion. Removal time of the prosthesis 4 weeks.
Intervention Type
Procedure
Intervention Name(s)
Surgical resection
Intervention Description
The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
Primary Outcome Measure Information:
Title
Quality of life of patients
Description
Percentage of patients with an increase of more than 30 points in the Inflammatory Bowel Disease Questionnaire (IBDQ-32) quality of life index. The higher the better.
Time Frame
One year of follow-up
Secondary Outcome Measure Information:
Title
Percentage of patients with clinical recurrence
Description
Percentage of patients with clinical recurrence (scale of obstructive symptoms 0-6) and costs. The lower the better.
Time Frame
One year of follow-up
Title
Percentage of complications
Description
Percentage of complications and costs.
Time Frame
One year of follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-80 years of age. Crohn's disease with predominantly de novo fibrotic stenosis* confirmed by endoscopic and radiological tests, accessible by endoscopy (colonoscopy). Patients with known stenosis previously treated with stenting and/or dilation performed over one year before the date of inclusion. Symptomatology of intestinal occlusion-subocclusion. Refractoriness to conventional medical treatment (non-response to the usual accelerated step-up therapeutic approach). Stenosis length < 10 cm. Maximum of 2 stenoses. Informed consent from patient. Exclusion Criteria: No informed consent from the patient. Complicated stenosis with abscess, fistula or significant activity associated with CD not limited to the area of the stenosis. Patients with known stenosis previously treated with stenting and/or dilation performed < 1 year before the date of inclusion. Pregnancy or lactation. Any clinical situation that prevents the performance of endoscopy or surgery. Stenosis not accessible by endoscopy. Asymptomatic patient. Stenosis length ≥ 10 cm. Presents with > 2 stenoses. Severe coagulation disorders (platelets < 70000; INR > 1.8).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna Casas
Phone
635 899 553
Email
secretariacientifica2@geteccu.org
First Name & Middle Initial & Last Name or Official Title & Degree
Eugeni Domènech
Email
eugenidomenech@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carme Loras
Organizational Affiliation
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Germans Trias i Pujol
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Marin, MD
Facility Name
Hospital Universitario de Bellvitge
City
Hospitalet de Llobregat
State/Province
Barcelona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joan Gonals, MD
Facility Name
Althaia, xarxa assistencial universitaria de Manresa
City
Manresa
State/Province
Barcelona
ZIP/Postal Code
08243
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Empar Sainz, MD
Facility Name
Consorci Corporació Sanitària Parc Taulí
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
08208
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Albert Villoria, MD
Facility Name
Hospital Moisès Broggi
City
Sant Joan Despí
State/Province
Barcelona
ZIP/Postal Code
08970
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mercè Navarro, MD
Facility Name
Hospital Mutua de Terrassa
City
Terrassa
State/Province
Barcelona
ZIP/Postal Code
08221
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carme Loras, MD
Facility Name
Hospital Universitario de Cáceres
City
Cáceres
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carmen Dueñas, MD
Facility Name
Clínica Girona
City
Girona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Josep Trueta
City
Girona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xavier Aldeguer, Dr
First Name & Middle Initial & Last Name & Degree
David Busquets, MD
Facility Name
Hospital de Inca
City
Inca
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
José Reyes, MD
Facility Name
Hospital Universitari Arnau de Vilanova
City
Lleida
ZIP/Postal Code
25198
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ferran Gonzalez-Huix, MD
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariló Martín, MD
Facility Name
Hospital Universitario Ramon y Cajal
City
Madrid
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paco Mesonero, MD
Facility Name
Hospital de Terrassa
City
Terrassa
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Monfort, MD
Facility Name
Hospital Clínico de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MÍGUEL MÍNGUEZ PÉREZ, MD
First Name & Middle Initial & Last Name & Degree
Maia Boscó, MD
First Name & Middle Initial & Last Name & Degree
Vicente Sanchiz, MD
Facility Name
Hospital Universitari La Fe
City
Valencia
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elena Cerrillo, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21530745
Citation
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785-94. doi: 10.1053/j.gastro.2011.01.055.
Results Reference
background
PubMed Identifier
18054751
Citation
Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I; IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8. doi: 10.1016/j.cgh.2007.09.002.
Results Reference
background
PubMed Identifier
19861953
Citation
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb;105(2):289-97. doi: 10.1038/ajg.2009.579. Epub 2009 Oct 27.
Results Reference
background
PubMed Identifier
17903236
Citation
Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: Endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1457-64. doi: 10.1111/j.1365-2036.2007.03532.x. Epub 2007 Sep 28.
Results Reference
background
PubMed Identifier
26358739
Citation
Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D, Abercrombie J, Ragunath K, Sanders DS, Arnott I, Wilson G, Bloom S, Arebi N; Crohn's Stricture Study (CroSS) Group. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures. Aliment Pharmacol Ther. 2015 Nov;42(10):1137-48. doi: 10.1111/apt.13388. Epub 2015 Sep 11.
Results Reference
background
PubMed Identifier
27126619
Citation
Navaneethan U, Lourdusamy V, Njei B, Shen B. Endoscopic balloon dilation in the management of strictures in Crohn's disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc. 2016 Dec;30(12):5434-5443. doi: 10.1007/s00464-016-4902-1. Epub 2016 Apr 28.
Results Reference
background
PubMed Identifier
2394349
Citation
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990 Oct;99(4):956-63. doi: 10.1016/0016-5085(90)90613-6.
Results Reference
background
PubMed Identifier
19568226
Citation
Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lemann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009 Aug;104(8):2089-96. doi: 10.1038/ajg.2009.301. Epub 2009 Jun 30.
Results Reference
background
PubMed Identifier
29610018
Citation
Loras C, Mayor V, Fernandez-Banares F, Esteve M. Study of the standard direct costs of various techniques of advanced endoscopy. Comparison with surgical alternatives. Dig Liver Dis. 2018 Jul;50(7):689-697. doi: 10.1016/j.dld.2018.03.002. Epub 2018 Mar 12.
Results Reference
background
PubMed Identifier
25895008
Citation
Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2015 May;21(5):1187-94. doi: 10.1097/MIB.0000000000000271.
Results Reference
background
PubMed Identifier
27660342
Citation
Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, Laureti S, Sampietro GM, Vucelic B, van der Woude CJ, Barreiro-de Acosta M, Maaser C, Portela F, Vavricka SR, Gomollon F; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017 Feb;11(2):135-149. doi: 10.1093/ecco-jcc/jjw169. Epub 2016 Sep 22. Erratum In: J Crohns Colitis. 2022 Aug 16;:
Results Reference
background
PubMed Identifier
28498901
Citation
Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, de Buck van Overstraeten A, Burke JP, Buskens CJ, Colombo F, Dias JA, Eliakim R, Elosua T, Gecim IE, Kolacek S, Kierkus J, Kolho KL, Lefevre JH, Millan M, Panis Y, Pinkney T, Russell RK, Shwaartz C, Vaizey C, Yassin N, D'Hoore A. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohns Colitis. 2018 Jan 5;12(1):1-16. doi: 10.1093/ecco-jcc/jjx061. No abstract available.
Results Reference
background
PubMed Identifier
31144122
Citation
Andujar X, Loras C, Gonzalez B, Socarras M, Sanchiz V, Bosca M, Domenech E, Calafat M, Rodriguez E, Sicilia B, Calvet X, Barrio J, Guardiola J, Iglesias E, Casanova MJ, Ber Y, Monfort D, Lopez-Sanroman A, Rodriguez-Lago I, Bujanda L, Marquez L, Martin-Arranz MD, Zabana Y, Fernandez-Banares F, Esteve M; ENEIDA registry of GETECCU. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surg Endosc. 2020 Mar;34(3):1112-1122. doi: 10.1007/s00464-019-06858-z. Epub 2019 May 29. Erratum In: Surg Endosc. 2019 Jun 18;:
Results Reference
background
PubMed Identifier
22161935
Citation
Attar A, Maunoury V, Vahedi K, Vernier-Massouille G, Vida S, Bulois P, Colombel JF, Bouhnik Y; GETAID. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012 Oct;18(10):1849-54. doi: 10.1002/ibd.22844. Epub 2011 Dec 11.
Results Reference
background
PubMed Identifier
21542067
Citation
Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn's disease: report of nine-year follow-up and review of the literature. Inflamm Bowel Dis. 2012 Mar;18(3):506-12. doi: 10.1002/ibd.21739. Epub 2011 May 3.
Results Reference
background
PubMed Identifier
22966851
Citation
Loras C, Perez-Roldan F, Gornals JB, Barrio J, Igea F, Gonzalez-Huix F, Gonzalez-Carro P, Perez-Miranda M, Espinos JC, Fernandez-Banares F, Esteve M. Endoscopic treatment with self-expanding metal stents for Crohn's disease strictures. Aliment Pharmacol Ther. 2012 Nov;36(9):833-9. doi: 10.1111/apt.12039.
Results Reference
background
PubMed Identifier
27014743
Citation
Loras Alastruey C, Andujar Murcia X, Esteve Comas M. The role of stents in the treatment of Crohn's disease strictures. Endosc Int Open. 2016 Mar;4(3):E301-8. doi: 10.1055/s-0042-101786.
Results Reference
background
Citation
Multicenter prospective randomized study to compare endoscopic treatment of strictures in crohn´s disease: self-expanding metal stents vs endoscopic balloon dilation. Protdilat study. Andujar X, Loras Alastruey C, Gornals J.B, Guardiola J., Sanchiz V., Bosca M., Brullet E., Sicília Aladrén B., Naranjo Rodríguez A., Martín-Arranz M.D., Dueñas-Sadornil C., Foruny J.R., Barrio Andrés J., Monfort Miquel D., Busquets Casals D., Pineda J.R., Pérez-Roldán F., Pons Beltrán V., González-Huix Lladó F., Sainz E., Gonzalez B.9,, Reyes Moreno J., Fernández-Bañares F.9,, Esteve M. 27rd United European Gastroenterology Week (UEGW). Barcelona 2019. UNITED EUROPEAN GASTROENTEROLOGY Barcelona 22- 24 October 2019.
Results Reference
background

Learn more about this trial

Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease.

We'll reach out to this number within 24 hrs